All In Biotech

Drug Trial Radar · NCT06320067

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

Studying Treatments in Patients Receiving Androgen Deprivation Therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and Radiation Efficacy: A 2nd Multi-arm Multi-stage Randomised Controlled Trial (STAMPEDE2).

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,360

Planned (sponsor's estimate)

Start

Jun 11, 2024

Primary completion

Apr 2031

Study completion Mar 2032

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK; Novartis
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

STAMPEDE2 is a clinical trial comparing two new treatments with standard of care in people with prostate cancer that has spread to other parts of the body and is responsive to hormone therapy. People from all backgrounds and ethnicities are encouraged to take part and multiple hospitals across the UK are involved. University College London is running the trial. Each comparison within the trial has its own control arm where people get the best standard of care (Arm A) versus a research arm where a new treatment is added to standard of care. Participants are allocated to an arm by a computerised system with a 50% chance of getting the research treatment. Comparison S: Arm A versus Arm S (Stereotactic Ablative Body Radiotherapy (SABR)) - Tests whether giving targeted doses of radiotherapy (SABR) to parts of the body where the cancer has spread slows the spread of the cancer and improves survival. 2476 people will be in this comparison. Comparison P: Arm A versus Arm P (PSMA-Lutetium (177Lu-PSMA-617)) - Tests whether giving a radioactive material (177Lu-PSMA-617) that targets prostate cancer cells slows the spread of the cancer and improves survival. 1756 people will be in this comparison. All participants will be followed up with scans and tests to monitor their cancer. Doctors will check for any side effects from the treatments. Treatments will be stopped if side effects are serious, or people no longer wish to take the treatments.

Conditions

  • Prostate Cancer Metastatic

Interventions

  • Stereotactic Ablative Body Radiotherapy (SABR)Radiation

    SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 27-30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.

  • 177Lu-PSMA-617Other

    177Lu-PSMA-617 is a nuclear medicine therapy. Patients will receive 177Lu-PSMA-617 to a dose of 7.4GBq. Each cycle will consist of 2 doses, 1 week apart (on day 1 and day 8) and will last 6 weeks. Treatment will be given for up to 3 cycles (6 doses).

  • Androgen Deprivation Therapy (ADT)Drug

    Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.

  • Androgen Receptor Signalling Inhibitor (ARPI)Drug

    Second generation ARPI (Abiraterone Acetate and Prednisolone, Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines. Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess. Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles. Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring. Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles.

  • Radiotherapy to Prostate ± Pelvic NodesRadiation

    Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 44-47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).

  • DocetaxelDrug

    Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Final analysis for each comparison triggered when adequate number of death events have occurred in control arm of each comparison. Anticipate final reporting for OS in Comparison S: ~84 months (7 years) from FPFV, P: ~64 months (5.3 years) from FPFV.

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Mount Vernon Hospital

    Barnsley, United Kingdom · Recruiting

  • Addenbrookes

    Cambridge, United Kingdom · Recruiting

  • Royal Devon University Hospital Trust

    Exeter, United Kingdom · Recruiting

  • Royal Devon & Exeter Hospital

    Exeter, United Kingdom · Recruiting

  • The Princess Alexandra Hospital

    Harlow, United Kingdom · Recruiting

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom · Recruiting

  • The Royal Marsden Hospital

    London, United Kingdom · Recruiting

  • Barts Health NHS Trust

    London, United Kingdom · Recruiting

  • North Middlesex Hospital

    London, United Kingdom · Recruiting

  • Royal Free Hospital

    London, United Kingdom · Recruiting

  • The James Cook University Hospital

    Middlesbrough, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • Derriford Hospital

    Plymouth, United Kingdom · Recruiting

  • Queen Alexandra Hospital

    Portsmouth, United Kingdom · Recruiting

  • Barking, Havering and Redbridge University Hospitals NHS Trust

    Romford, United Kingdom · Recruiting

  • North Tees Health NHS Trust

    Stockton-on-Tees, United Kingdom · Recruiting

  • The Royal Marsden Hospital

    Sutton, United Kingdom · Recruiting

  • Kings Mill Hospital

    Sutton in Ashfield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.